ClinicalTrials.gg
CompletedNCT00080275Updated Nov 1, 2006

Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)

A Phase 3 interventional study of Niacin Extended-Release and simvastatin Tablets in Hypercholesterolemia, sponsored by Kos Pharmaceuticals. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2006-11-01.

Sponsored by Kos Pharmaceuticals (formerly part of Abbott) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 14 studies testing niacin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. Niacin · Hypercholesterolemia.

Enrollment
3rd of 13
600 · median 64
Started
2004
with 1 other
Phase 3
6 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
Kos Pharmaceuticals

Among the 14 studies testing niacin in Hypercholesterolemia, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 3, and was the 2nd registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 14 studies testing niacin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About niacin

Niacin: first FDA approval 1957 (WAMPOCAP), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing niacin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).

At least 600 subjects with a similar medical condition will take part in this study.

Read the detailed description

Objectives:

To evaluate the safety and efficacy of the combination product niacin ER and simvastatin (NS) in patients with primary type II dyslipidemia and to descriptively compare flushing rates between two Titration Schedules for NS.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Niacin
  • Statin
  • Zocor
  • Simvastatin
  • Coronary Heart Disease
  • Dyslipidemia
  • Atherosclerosis
  • Hypercholesterolemia
  • Stroke
  • High-Density Lipoprotein Cholesterol
  • Low-Density Lipoprotein Cholesterol
  • Lipoprotein
  • Lipid
  • Niacin ER/simvastatin
  • Total Cholesterol
  • Triglycerides
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has primary Type II hyperlipidemia or mixed dyslipidemia.
  • If the patient is currently taking a lipid modifying medication other than Zocor \& he/she is willing to discontinue this medication
  • LDL-C levels and/or non HDL-C levels above normal.
  • Reasonable compliance with a standard cholesterol-lowering diet for a minimum of 4 weeks prior to screening and for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Patient has an allergy, , or intolerance to niacin, statins, or their derivatives.
  • ≥ 9% in diabetic patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants

Interventions

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008;8(2):69-81. doi: 10.2165/00129784-200808020-00001. PubMed 18422390 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00080275
First posted
Mar 29, 2004
Start date
Mar 2004
Last update
Nov 1, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niacin · Simvastatin

Start the discussion